Today: 17 May 2026
Wesfarmers share price slides to A$76 as ASX rout bites — what moved ASX:WES today
4 March 2026
1 min read

Wesfarmers share price slides to A$76 as ASX rout bites — what moved ASX:WES today

Sydney, March 4, 2026, 17:46 (AEDT) — After-hours

Wesfarmers Ltd (WES.AX) slipped 1.5% to finish at A$76.07 on Wednesday, chalking up a second consecutive decline. Over two sessions, the stock has dropped roughly 5%. Shares moved in a range from A$75.41 to A$76.86, with volume at around 1.51 million.

Australian equities took a hit, the S&P/ASX 200 tumbling 1.9% to close at 8,901—its steepest drop since February. Brent crude, meanwhile, pushed 1.6% higher to $82.70 a barrel. By late afternoon, the Australian dollar had slipped 0.5% to 69.95 U.S. cents.

Stocks tumbled across Asian markets as fears of a Middle East conflict driving up oil prices rattled investors, with many worried about inflation flaring up and central banks delaying interest-rate cuts. “Asia’s selloff is turning disorderly,” said Charu Chanana, Saxo’s chief investment strategist in Singapore. IG’s Tony Sycamore pointed to “de-risking of portfolios.” reuters.com

Wesfarmers is dealing with a familiar set of headaches: rising fuel and freight expenses, a weaker currency, and rate uncertainty all squeeze household budgets and push up operating costs for the retail giant.

Stock-specific headlines were scarce this day. Wesfarmers’ ASX announcements page lists its latest filings as dividend updates posted back on Feb. 26.

For income-focused investors, the next milestone is close: Wesfarmers plans to pay an interim dividend of 102 Australian cents per share on March 31, labeling it as fully franked—so investors will get the full benefit of attached Australian corporate tax credits.

Expect the market to keep pressing on the broader consumer sector. Grocery and general merchandise players—think Woolworths and Coles—are usually among the first to feel any move in inflation expectations.

But the trade isn’t locked in. Oil comes off, or headlines hint at de-escalation, and those defensive retailers might catch a bid alongside the broader tape. Should energy hold firm, though, the squeeze on budgets and margins drags out.

Thursday brings a focus on crude prices, the Australian dollar, and any new war headlines—traders trying to gauge if the jolt is wearing off. Wesfarmers investors are looking ahead to the March 31 dividend payout.

Stock Market Today

  • Monster Beverage (MNST) Stock Near Fair Value After Multi-Year Gains
    May 16, 2026, 9:18 PM EDT. Monster Beverage (MNST) has delivered strong returns, rising nearly 89% over five years. The stock recently traded at around $87, modestly above its estimated intrinsic value of $80.02 based on a Discounted Cash Flow (DCF) model. This valuation approach projects Monster's free cash flow growing from $1.94 billion to over $3 billion by 2030. Despite impressive share price gains, the DCF suggests Monster is roughly 8.8% overvalued, indicating current prices are close to fair value rather than significantly overpriced. While the company's position in the US energy drink market supports growth prospects, its valuation score was 0 out of 6 on standard metrics, urging caution for new investors. Traders should monitor valuation shifts and market developments to time entries appropriately.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 04.03.2026

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform
Next Story

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform

Go toTop